David Metrikin, MD
Retina Specialist · El Paso, TXNPI 1902809262
Payments from drug & device makers
What this record shows
18 manufacturers reported payments, led by US Retina LLC at 54.5% of the total. Reporting peaked in 2022 at $3,265 and has fallen 69.3% since, to $1,003 in 2025.
Across 75 payments — averaging $146.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$6K
- Genentech USA, Inc.$683
- Alcon$674
- Regeneron Healthcare Solutions, Inc.$626
- Regeneron$497
- Astellas Pharma US Inc$407
- plus $2K from 12 others
What the payments were for
- Food & beverage$5,00245%
- Ownership interest$5,99255%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $5,992 |
| Genentech USA, Inc. | 10 | $683 |
| Alcon | 8 | $674 |
| Regeneron Healthcare Solutions, Inc. | 9 | $626 |
| Regeneron | 4 | $497 |
| Astellas Pharma US Inc | 4 | $407 |
| Alimera Sciences, Inc. | 5 | $355 |
| AbbVie(2 entities) | 11 | $277 |
| Carl Zeiss Meditec USA, Inc. | 2 | $267 |
| Amgen | 2 | $196 |
| Apellis Pharmaceuticals, Inc. | 3 | $190 |
| Biogen | 2 | $165 |
| Sandoz | 2 | $143 |
| Novartis | 2 | $118 |
| Eyepoint US, Inc. | 2 | $111 |
| Bausch & Lomb Americas Inc. | 1 | $111 |
| Spark Therapeutics, Inc. | 1 | $99 |
| Harrow Eye, LLC | 1 | $85 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$632
- VABYSMO$377
- EYLEA HD$348
- Lucentis$252
- Constellation$238
- Izervay$236
- Iluvien$227
- VERACITY SURGICAL$160
- NGENUITY$139
- Syfovre$123
- SUSVIMO$122
- VISUDYNE$111
- Retina Workplace$108
- BEOVU$100
How this compares
$10,995 in reported general payments places this provider in the 80th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 98 | $3,062 |
| MoxifloxacinMoxifloxacin Hcl | 64 | $1,925 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $1,365 |
| Dorzolamide Hcl | 31 | $574 |
| Cyclopentolate Hcl | 33 | $493 |
| Atropine Sulfate | 14 | $346 |
| Timolol Maleate | 38 | $287 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $121 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in El Paso
- Dinesh BahlEl Paso$13K
- Jeremy CuthbertsonEl Paso$12K
- Daniel KasugaEl Paso$9K
- Gregory TrubowitschEl Paso$8K
- Richard HwangEl Paso$3K
- Erica Alvarez GonzalezEl Paso$2K
- Courtney CrawfordBurleson$342K
- Jeremiah BrownSchertz$339K
- Victor GonzalezMcAllen$335K
- Judy KimDallas$256K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.